Status:
COMPLETED
Oral Losartan in Prevention of Post-ERCP Paancreatitis
Lead Sponsor:
Ain Shams University
Conditions:
Post-ERCP Acute Pancreatitis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50 patients underwent...
Eligibility Criteria
Inclusion
- Any adult patient indicated for ERCP
- Patients with obstructive jaundice.
- Patients with dilated intra-hepatic or extra-hepatic bile ducts due to malignant or benign lesions.
Exclusion
- Patients refusing to undergo the procedure or signing the informed consent
- Patients with clinically evident acute pancreatitis before the procedure
- Patients with previous endoscopic or surgical sphincterotomy
- Patients with current use of losartan
- Patients who are allergic or hypersensitive to losartan or hydro soluble contrast solutions
- Patients receiving NSAIDS within a week prior to assessment
- Patients with severe co-morbid conditions as cardiovascular disease, renal failure or decompensated liver cirrhosis.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04049734
Start Date
January 1 2015
End Date
March 1 2017
Last Update
August 9 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.